Practo Crosses $100 Million GMV as AI-Driven Healthcare Marketplace Scales Globally

Practo's healthcare marketplace has crossed $100 million GMV, a threshold that signals the accelerating commercialisation of agentic AI systems across clinical and administrative workflows — a shift with direct relevance to digital health procurement and vendor qualification teams operating under 21 CFR Part 11 and equivalent data integrity frameworks.

The platform now handles more than 20,000 AI-driven calls and chats daily, processing patient interactions through automated systems that span appointment scheduling, triage routing, and care coordination. For health system operators and QA directors evaluating third-party digital platforms, the scale of these agentic workflows raises validated-system questions: how are AI decision pathways documented, audited, and controlled when volume reaches this level?

Practo's expansion is occurring across multiple geographies simultaneously, compressing the timeline between domestic deployment and international regulatory exposure. Organisations in markets with stricter health data governance — including those aligned to ICH Q10-adjacent quality management principles for digital systems — will need to assess whether the platform's AI infrastructure meets local compliance requirements before integration into patient-facing or supply-chain-adjacent processes.

The GMV figure itself reflects transaction volume across the marketplace, encompassing consultations, diagnostics, and pharmacy services. That breadth means the platform touches multiple regulated categories, each carrying distinct documentation and audit-trail obligations depending on jurisdiction. Procurement leads at hospital networks or pharma-adjacent health services should map those obligations against Practo's current compliance disclosures before expanding use.

The 20,000-daily-interaction figure will be a measurable baseline against which regulators and enterprise clients can track system reliability, error rates, and escalation protocols as the platform continues to scale.

Source: Media4Growth via Indian Pharma Post, 6 May 2026.